CARTCREU更新
非注册临床 vs 注册性临床
又一个potential bic
Gracecell的FasTCAR的PK
2020-03-05
GSK's strategies to get cell therapies into the clinic faster and cheaper
cytoDRIVE platform for controlling TcellRx activity by guiding degradation or activation of CAR T machinery and/or armor components to dial-in immunotherapy
Cell therapy trials that have been carried out at the Christie Hosp, Manchester UK. Each cost >£1m
TC Biopharm reckons gamma-delta T cell based allo product could get cost of goods down to $5,000/pt
TC Biopharm: allogeneic gamma-delta Car-T (TCB003-006), based on claim that healthy cells don’t express IPP
Adicet Bio: gamma delta cells on targeting intracellular antigens for off-the-shelf
remarkable clinical efficacy and cost effectiveness of gamma-delta allogenic T cells as well as the latest developments in gamma-delta CAR-T cells.
new gamma-delta TCellRx platforms
Artemis platform for TCR-like
An interesting platform concept for merging gamma-delta TCR-like signaling with scFv-like binding to CAR targets
how multiTAA T cells overcome the challenges of CAR T cells and are making remarkable headway into treating challenging solid tumours
pipeline progression of autologous and allogeneic CAR-T cell therapies.
PI3K inhibition and NKGD2 blocking used during manufacture to enhance phenotype and inhibit fratricide.
Atarabio's allogeneic EBV CAR-T cells
PK, PD, and Tox for axi-cel
“PK is the most important correlate of response with the key metric being peak CAR-T expansion.” Prophylactic IL6i helps to reinforce role of myeloid cells in neurotox model.
Proliferation rate during manufacturing and Tscm phenotype in product positively correlate. CD20+ CD19- relapse most common.
how collaboration between commercial, academic and clinical partners is accelerating UK based access to advanced therapies with the ATTC network
how to provide consistent raw materials to our cell therapy clients
opps & challenges of running cell therapy clinical trials in Europe,